GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » YoY EBITDA Growth

Paradigm Biopharmaceuticals (ASX:PAR) YoY EBITDA Growth : -41.74% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Paradigm Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -41.74%.

Paradigm Biopharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.16.

Paradigm Biopharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Paradigm Biopharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals YoY EBITDA Growth Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only 15.94 -175.86 -1.88 -9.82 -11.17

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.17 -2.68 -35.29 -41.74 52.17

Paradigm Biopharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Paradigm Biopharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (A: Jun. 2024 )
=(EBITDA per Share (A: Jun. 2024 )-EBITDA per Share (A: Jun. 2023 ))/ | EBITDA per Share (A: Jun. 2023 ) |
=(-0.199--0.179)/ | -0.179 |
=-11.17 %

Paradigm Biopharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.163--0.115)/ | -0.115 |
=-41.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:BOT ASX:RAC ASX:OPT ASX:PYC ASX:PIQ ASX:RCE ASX:BIT ASX:CU6 ASX:ALA ASX:DXB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PBIGF:USA
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Website
https://www.paradigmbiopharma.com
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.